SCHEDULE 13G/A: Luther King Capital Management and J. Luther King Jr. Disclose Significant Stakes in scPharmaceuticals Inc.

Luther King Capital Management Corporation and J. Luther King Jr. have filed an amended Schedule 13G, disclosing beneficial ownership of 5.7% and 6.0% respectively, in scPharmaceuticals Inc. common stock as of December 31, 2024.

Summary

• Luther King Capital Management Corporation reported beneficial ownership of 2,857,910 shares, representing 5.7% of scPharmaceuticals Inc.'s Common Stock.
• J. Luther King, Jr. reported beneficial ownership of 2,980,410 shares, representing 6.0% of scPharmaceuticals Inc.'s Common Stock.
• Both Luther King Capital Management Corporation and J. Luther King, Jr. hold sole voting and sole dispositive power over their respective reported shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of scPharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without indicating positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a routine disclosure of significant beneficial ownership by an investment adviser and an individual, indicating their passive investment in scPharmaceuticals Inc. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact that these entities see value in holding a stake in a pharmaceutical company.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant ownership stakes, which can influence perceptions of institutional interest and stability.

Key Dates

Keywords

scPharmaceuticals Inc., Luther King Capital Management Corporation, J. Luther King Jr., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser